Clinical Trial
doi: 10.1023/a:1015441428154.Efficacy of porcine secretin in children with autism and pervasive developmental disorder
Affiliations
- PMID:12108616
- DOI: 10.1023/a:1015441428154
Item in Clipboard
Clinical Trial
Efficacy of porcine secretin in children with autism and pervasive developmental disorder
Janet K Kern et al. J Autism Dev Disord.2002 Jun.
Display options
Format
Display options
Format
Abstract
Secretin, a gastrointestinal (GI) hormone, was reported in a preliminary study to improve language and behavior in children with autism/pervasive developmental disorder (PDD) and chronic diarrhea. To determine the efficacy of secretin, we completed a double-blind, placebo-controlled, crossover (3 weeks) study in children with autism/PDD and various GI conditions using a single dose of intravenous porcine secretin. Children with chronic, active diarrhea showed a reduction in aberrant behaviors when treated with the secretin but not when treated with the placebo. Children with no GI problems are unaffected by either secretin or placebo. The improvement seen with secretin in children with autism/PDD and chronic diarrhea suggests that there may be a subtype of children with autism/PDD who respond to secretin.
Similar articles
- Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.Lightdale JR, Hayer C, Duer A, Lind-White C, Jenkins S, Siegel B, Elliott GR, Heyman MB.Lightdale JR, et al.Pediatrics. 2001 Nov;108(5):E90. doi: 10.1542/peds.108.5.e90.Pediatrics. 2001.PMID:11694674
- Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism.Carey T, Ratliff-Schaub K, Funk J, Weinle C, Myers M, Jenks J.Carey T, et al.J Autism Dev Disord. 2002 Jun;32(3):161-7. doi: 10.1023/a:1015493412224.J Autism Dev Disord. 2002.PMID:12108617Clinical Trial.
- A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.Corbett B, Khan K, Czapansky-Beilman D, Brady N, Dropik P, Goldman DZ, Delaney K, Sharp H, Mueller I, Shapiro E, Ziegler R.Corbett B, et al.Clin Pediatr (Phila). 2001 Jun;40(6):327-31. doi: 10.1177/000992280104000604.Clin Pediatr (Phila). 2001.PMID:11824175Clinical Trial.
- Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials.Sturmey P.Sturmey P.Res Dev Disabil. 2005 Jan-Feb;26(1):87-97. doi: 10.1016/j.ridd.2004.09.002.Res Dev Disabil. 2005.PMID:15590241Review.
- Secretin for the treatment of autism.McQueen JM, Heck AM.McQueen JM, et al.Ann Pharmacother. 2002 Feb;36(2):305-11. doi: 10.1345/aph.19113.Ann Pharmacother. 2002.PMID:11847953Review.
Cited by
- Gastrointestinal factors in autistic disorder: a critical review.Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald JF, McDougle CJ.Erickson CA, et al.J Autism Dev Disord. 2005 Dec;35(6):713-27. doi: 10.1007/s10803-005-0019-4.J Autism Dev Disord. 2005.PMID:16267642Review.
- Intravenous secretin for autism spectrum disorders (ASD).Williams K, Wray JA, Wheeler DM.Williams K, et al.Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD003495. doi: 10.1002/14651858.CD003495.pub3.Cochrane Database Syst Rev. 2012.PMID:22513913Free PMC article.Review.
- Evidence of neurodegeneration in autism spectrum disorder.Kern JK, Geier DA, Sykes LK, Geier MR.Kern JK, et al.Transl Neurodegener. 2013 Aug 8;2(1):17. doi: 10.1186/2047-9158-2-17.Transl Neurodegener. 2013.PMID:23925007Free PMC article.
- In children with autism, is intravenous secretin more effective than placebo in improving social skills, communication, behaviour or global functioning?: Part A: Evidence-based answer and summary.Petryk S.Petryk S.Paediatr Child Health. 2004 Apr;9(4):244-5. doi: 10.1093/pch/9.4.244.Paediatr Child Health. 2004.PMID:19655017Free PMC article.No abstract available.
- Secretin as a treatment for autism: a review of the evidence.Esch BE, Carr JE.Esch BE, et al.J Autism Dev Disord. 2004 Oct;34(5):543-56. doi: 10.1007/s10803-004-2549-6.J Autism Dev Disord. 2004.PMID:15628608Review.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources